CD22-specific humanized antibody and chimeric antigen receptor using the same

Abstract

The present invention relates to a humanized antibody specific to CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody that specifically binds to CD22, a chimeric antigen receptor comprising the antibody or a CD19×CD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition comprising them for preventing or treating a disease mediated by B cells. In the present invention, CD22-CAR-T cells and bispecific CD19×CD22-CAR-T cells, which were generated based on a humanized antibody that specifically binds to CD22, were confirmed to effectively recognize the CD22 antigen, activate CAR-T cells, and effectively kill cells expressing CD22. Furthermore, since the bispecific CD19×CD22-CAR-T cells of the present invention have been confirmed to exhibit excellent anti-tumor effects in animal models, the humanized antibody-based CD22-CAR-T cells and bispecific CD19×CD22-CAR-T cells of the present invention that specifically bind to CD22 can be usefully used as compositions for preventing or treating diseases associated with CD22 (or CD19) expression or diseases associated with B cells.

Description

[Technical field]

[0001] The present invention relates to a humanized antibody specific to CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody that specifically binds to CD22, a chimeric antigen receptor comprising the antibody or a CD19×CD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition comprising them for preventing or treating a disease mediated by B cells. [Background technology]

[0002] CD22 is expressed on most B-cell leukemias and lymphomas, including NHL, acute lymphocytic leukemia (B-ALL), chronic lymphocytic leukemia (B-CLL), and especially acute nonlymphocytic leukemia (ANLL).

[0003] Antibodies specific to CD22 have been developed for the treatment or diagnosis of diseases associated with CD22 expression. International Publication WO1998-041641 discloses a recombinant anti-CD22 antibody having cysteine ​​residues at the VH44 and VL100 positions, and International Publication WO1998-042378 discloses an anti-CD22 antibody for the treatment of B-cell malignancies.

[0004] To produce therapeutic antibodies such as those mentioned above, monoclonal antibodies are usually produced using mice, but non-human antibodies such as mouse-derived monoclonal antibodies are considered foreign antigens in the human body and have problems such as the fact that they induce immune responses and have a short half-life, limiting their therapeutic effectiveness.

[0005] To solve the above problems, humanized antibodies have been developed in which the remaining parts of the antibody, except for the antigen-binding region, are replaced with human antibodies. The currently used method of replacing mouse antibodies with humanized antibodies involves selecting the human antibody gene most similar to the antibody to be replaced, and replacing only the CDR site of the mouse antibody with the CDR site of the human antibody using a method called CDR grafting. Such humanized antibodies have the advantage of reducing immune responses in the human body because most of the genes are humanized.

[0006] Meanwhile, antibodies specific to the various B cell surface markers (antigens) mentioned above have been developed for the treatment of B cell diseases and disorders, autoimmune diseases, transplant rejection, etc. In addition to the CD22 antigen, CD19 is a commonly used antigen as a target, and clinical research on CAR-T cells targeting CD19 has also progressed significantly. However, there are differences in the expression level of target antigens depending on leukemia cells that do not express CD19, and single CAR or single CAR-T cell therapy that targets only one antigen may cause problems such as loss of target antigen due to immune evasion strategies of tumor cells. In fact, CD19-negative relapses that did not express CD19 have been observed in B cell ALL (acute lymphocytic leukemia) patients (up to 25% of B cell ALL patients who initially responded to CD19 CAR-T therapy), and this phenomenon was found before the resistance of tumor cells to CAR-T cell therapy (Maude, S.L., et al., N. Engl. J. Med., 378:439-448, 2018).

[0007] To solve this problem, dual or multiple antigen-targeting CAR-T cells are being investigated, which can target two antigens simultaneously, thereby reducing the possibility of antigen-loss variants. Summary of the Invention [Problem to be solved by the invention]

[0008] In the present invention, an antibody that binds to CD22 is selected to reduce immune responses in the human body, and is used to prepare a humanized anti-CD22 antibody, and the humanized anti-CD22 antibody of the present invention is used to prepare a chimeric antigen receptor and CAR-T cell that target CD22.

[0009] Furthermore, the present inventors prepared bispecific chimeric antigen receptors (bivalent CARs or bispecific CARs) and bispecific CAR-T cells that target not only CD22 but also CD19, and confirmed that the chimeric antigen receptors were normally expressed in the CD22-CAR-T cells and bispecific CD19×CD22-CAR-T cells produced according to the present invention, thereby completing the present invention.

[0010] It is an object of the present invention to provide a humanized antibody specific for CD22, a polynucleotide encoding said antibody, a vector expressing said antibody, and a recombinant cell transformed with said vector.

[0011] Another object of the present invention is to provide a chimeric antigen receptor comprising said humanized antibody specific for CD22, a polynucleotide encoding said chimeric antigen receptor, a vector comprising said polynucleotide, and an immune effector cell expressing a chimeric antigen receptor comprising said polynucleotide or vector.

[0012] Another object of the present invention is to provide a bispecific chimeric antigen receptor comprising antibodies specific for CD19 and CD22, a polynucleotide encoding said bispecific chimeric antigen receptor, a vector comprising said polynucleotide, and an immune effector cell expressing the bispecific chimeric antigen receptor comprising said polynucleotide or vector.

[0013] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating a disease mediated by B cells, comprising the immune effector cells. [Means for solving the problem]

[0014] In order to achieve one of the above objectives, The present invention provides a humanized antibody or fragment thereof that specifically binds to CD22, comprising a heavy chain variable region represented by the amino acid sequence of SEQ ID NO:11 and a light chain variable region represented by the amino acid sequence of SEQ ID NO:12; or a heavy chain variable region represented by the amino acid sequence of SEQ ID NO:15 and a light chain variable region represented by the amino acid sequence of SEQ ID NO:16.

[0015] Furthermore, the present invention provides a polynucleotide encoding the humanized antibody or a fragment thereof that specifically binds to CD22.

[0016] Alternatively, the present invention provides a vector comprising a polynucleotide encoding the humanized antibody or a fragment thereof that specifically binds to CD22.

[0017] Furthermore, the present invention provides a recombinant cell that is transformed with the above vector and produces a humanized antibody or a fragment thereof that specifically binds to CD22.

[0018] To achieve another purpose, The present invention relates to a chimeric antigen receptor (CAR), comprising a CD22 binding domain; a transmembrane domain; a costimulatory domain; and an intracellular signal transduction domain, Here, the present invention provides a chimeric antigen receptor that targets CD22, characterized in that the CD22-binding domain is a humanized antibody or a fragment thereof that specifically binds to CD22, comprising a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 11 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 12; or a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 15 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 16.

[0019] In a preferred exemplary embodiment of the invention, the transmembrane domain may be a protein selected from the group consisting of CD8α, CD4, CD28, CD137, CD80, CD86, CD152 and PD1, the costimulatory domain may be a protein selected from the group consisting of CD28, 4-1BB, OX-40 and ICOS, and the intracellular signaling domain may be derived from CD3ζ.

[0020] In a preferred exemplary embodiment of the invention, the polypeptide may further comprise a hinge region between the C-terminus of the binding domain and the N-terminus of the transmembrane domain, the hinge region may be derived from CD8α.

[0021] The present invention further provides a polynucleotide encoding the chimeric antigen receptor.

[0022] Furthermore, the present invention provides a vector comprising a polynucleotide encoding the chimeric antigen receptor.

[0023] Furthermore, the present invention provides an immune effector cell that contains a polynucleotide encoding the chimeric antigen receptor or a vector containing the polynucleotide and expresses the chimeric antigen receptor.

[0024] To achieve another purpose, The present invention provides a bispecific chimeric antigen receptor comprising a CD19-binding domain and a CD22-binding domain; a transmembrane domain; a costimulatory domain; and an intracellular signaling domain, The CD22-binding domain is an antibody or a fragment thereof that specifically binds to CD22, comprising: a heavy chain variable region comprising a CDR1 region represented by the amino acids of SEQ ID NO:1, a CDR2 region represented by the amino acids of SEQ ID NO:2, and a CDR3 region represented by the amino acids of SEQ ID NO:3; and a humanized antibody or a fragment thereof that specifically binds to CD22, comprising a light chain variable region comprising a CDR1 region represented by the amino acids of SEQ ID NO:4, a CDR2 region represented by the amino acids of SEQ ID NO:5, and a CDR3 region represented by the amino acids of SEQ ID NO:6.

[0025] In a preferred exemplary embodiment of the present invention, the CD19-binding domain and the CD22-binding domain may be linked in the following order: light chain variable region of an antibody that specifically binds to CD19 - heavy chain variable region of an antibody that specifically binds to CD22 - light chain variable region of an antibody that specifically binds to CD22 - heavy chain variable region of an antibody that specifically binds to CD19.

[0026] In another preferred exemplary embodiment of the present invention, the light chain variable site of the antibody that specifically binds to CD19 may comprise a CDR1 region represented by the amino acid sequence of SEQ ID NO: 44, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 45, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 46, and may preferably be represented by the amino acid sequence of SEQ ID NO: 48.

[0027] In yet another preferred exemplary embodiment of the present invention, the heavy chain variable site of the antibody that specifically binds to CD19 may comprise a CDR1 region represented by the amino acid sequence of SEQ ID NO: 41, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 42, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 43, and may preferably be represented by the amino acid sequence of SEQ ID NO: 47.

[0028] In yet another preferred exemplary embodiment of the invention, the transmembrane domain may be a protein selected from the group consisting of CD8α, CD4, CD28, CD137, CD80, CD86, CD152 and PD1, the costimulatory domain may be from the group consisting of CD28, 4-1BB, OX-40 and ICOS, and the intracellular signaling domain may be derived from CD3ζ.

[0029] In a preferred exemplary embodiment of the invention, the polypeptide may further comprise a hinge region between the C-terminus of the binding domain and the N-terminus of the transmembrane domain, the hinge region may be derived from CD8α.

[0030] Furthermore, the present invention provides a polynucleotide encoding said bispecific chimeric antigen receptor.

[0031] Furthermore, the present invention provides a vector comprising a polynucleotide encoding said bispecific chimeric antigen receptor.

[0032] Furthermore, the present invention provides an immune effector cell that comprises a polynucleotide encoding the bispecific chimeric antigen receptor or a vector containing the polynucleotide and expresses the bispecific chimeric antigen receptor.

[0033] To achieve another purpose, The present invention provides a pharmaceutical composition for preventing or treating a disease mediated by B cells, comprising the humanized antibody or a fragment thereof that specifically binds to CD22; or the immune effector cells.

[0034] In a preferred exemplary embodiment of the invention, the disease mediated by said B cells may be selected from the group consisting of tumors, lymphomas, non-Hogkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), Burkitt's lymphoma and mantle cell lymphoma. Effect of the Invention

[0035] In the present invention, we generated a humanized antibody that specifically binds to CD22 and used it to generate single CAR-T cells targeting CD22 and bispecific CAR-T cells targeting CD19 and CD22.

[0036] The CD22-CAR-T cells and bispecific CD19×CD22-CAR-T cells prepared in the present invention were confirmed to effectively recognize the CD22 antigen, activate the CAR-T cells, and effectively kill cells expressing CD22, based on a humanized antibody that specifically binds to CD22.

[0037] Furthermore, since the bispecific CD19×CD22-CAR-T cells of the present invention have been confirmed to exhibit excellent anti-tumor effects in animal models, the humanized antibody-based CD22-CAR-T cells and bispecific CD19×CD22-CAR-T cells of the present invention that specifically bind to CD22 can be usefully used as compositions for preventing or treating diseases associated with CD22 (or CD19) expression or diseases associated with B cells. [Brief description of the drawings]

[0038] FIG. 1 shows data on the binding ability of the 2G1 antibody and humanized 2G1 antibody selected in the present invention to CD22, as determined by FACS. FIG. 2 is a schematic diagram showing a chimeric antigen receptor (single CAR) targeting CD22. Figure 3 is a schematic diagram showing a method for producing CD22-CAR-expressing cells using a CD22-CAR-expressing lentivirus. FIG. 4 is a schematic diagram showing (A) a method for transducing a HEK293 cell line with a CD22-CAR expressing lentivirus and (B) a method for confirming the binding ability of the transduced HEK293 cells to the CD22 peptide. Figure 5 shows data confirming the expression levels of CD22-CAR in lentivirus-transduced HEK293FT cells expressing humanized anti-CD22 antibody, 2G1(V4) and 2G1(V12)-based CD22-CAR. FIG. 6 is a schematic diagram showing a method for generating CD22-CART cells using a CD22-CAR expressing lentivirus. Figure 7 is a schematic diagram showing (A) a method for producing CD22-CAR-T cells using peripheral blood mononuclear cells (PBMCs) and (B) a method for confirming the binding ability of the produced CD22-CAR-T cells to CD22 peptides. Figure 8 shows data confirming the CD22 binding capacity of humanized anti-CD22 antibody, 2G1(V4) and 2G1(V12)-based CD22-CAR-T cells. FIG. 9 shows data confirming the apoptotic effect of humanized anti-CD22 antibody 2G1(V4) and 2G1(V12)-based CD22-CAR-T cells on U2932 cells (CD22-expressing cells) and K562 cells (CD22 non-expressing cells). FIG. 10 shows data confirming the apoptotic effect of humanized anti-CD22 antibody 2G1(V4) and 2G1(V12)-based CD22-CAR-T cells on NALM6 cells (CD22-expressing cells) and K562 cells (CD22 non-expressing cells). FIG. 11 is a schematic diagram showing a bispecific chimeric antigen receptor (bispecific CAR) targeting CD19 and CD22. FIG. 12 is a schematic diagram showing how to generate CD19×CD22-CAR CD19-expressing cells using a lentivirus expressing a bispecific CD19×CD22-CAR targeting CD19 and CD22. FIG. 13 shows data confirming the expression levels of CD19×CD22(V4)-CAR in lentivirus-transfected HEK293FT cells expressing CD19×CD22-CAR based on anti-CD19 antibody FMC63 and humanized anti-CD22 antibody 2G1(V4). FIG. 14 shows data confirming the expression levels of CD19×CD22(V12)-CAR in lentivirus-transfected HEK293FT cells expressing anti-CD19 antibody and humanized anti-CD22 antibody 2G1(V12)-based CD19×CD22-CAR(V12). FIG. 15 is a schematic diagram showing how CD19×CD22-CAR-T cells are generated using lentivirus expressing CD19×CD22-CAR. Figure 16 shows data confirming the activation of CD19×CD22-CAR-T cells. In CD3+CD19×CD22-CAR-T cells (A), CD4+CD19×CD22-CAR-T cells (B), and CD8+CD19×CD22-CAR-T cells (C), it was confirmed that CD19×CD22-CAR-T cells simultaneously bound to CD22 peptide and CD19 peptide. Figure 17 shows data confirming the expression levels of IFNγ by (A) anti-CD19 antibody and mouse 2G1 antibody based CD19×CD22(mouse)-CAR-T cells, (B) anti-CD19 antibody and 2G1(V4) antibody based CD19×CD22(V4)-CAR-T cells, and (C) anti-CD19 antibody and 2G1(V12) antibody based CD19×CD22(V12)-CAR-T cells in the presence of target cells to confirm activation of CD19×CD22-CAR-T cells. Figure 18 shows data confirming the killing effect of CD19×CD22-CAR-T cells on (A) NALM6 cells (cells expressing CD19 and CD22), (B) K562 cells (cells not expressing CD19 or CD22), K562 / CD19+ cells (cells expressing CD19), K562 / CD22+ cells (cells expressing CD22), and K562 / CD19+ / CD22+ cells (cells expressing CD19 and CD22). Figure 19 shows (A) the luminescence expressed by NALM6 / Luc cells injected into mice was photographed using IVIS SpectrumCT to confirm the antitumor effect of CD19×CD22(V4)-CAR-T cells, and (B) the data showing the antitumor effect as a mouse survival rate curve in the experiment performed in (A). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] The present invention will be described in detail below.

[0040] A humanized antibody that specifically binds to CD22 In one aspect, the present invention provides a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 11, and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 12; or

[0041] The present invention relates to a humanized antibody or fragment thereof that specifically binds to CD22, comprising a heavy chain variable region represented by the amino acid sequence of SEQ ID NO:15 and a light chain variable region represented by the amino acid sequence of SEQ ID NO:16.

[0042] In the present invention, the term "humanized antibody" is an antibody that possesses an amino acid sequence that corresponds to that of an antibody produced by a human and / or that has been made using one of the techniques for making human antibodies as disclosed herein. This definition of a humanized antibody specifically excludes humanized antibodies that include a non-human antigen-binding portion.

[0043] In the present invention, the antibody may be a monoclonal antibody. In the present invention, the term "monoclonal antibody" is also called a single clone antibody or monoclonal antibody, which is an antibody produced by a single antibody-forming cell and is characterized by a uniform primary structure (amino acid sequence). It recognizes only one antigenic determinant and is generally produced by culturing hybridoma cells obtained by fusing cancer cells with antibody-producing cells, but it can also be produced using other recombinant protein-expressing host cells using the antibody gene sequence obtained. In addition, the above-mentioned antibody can also be used by humanizing the remaining portion excluding the CDR portion, if necessary.

[0044] As used herein, the term "CDR" or "complementarity determining region" refers to the non-contiguous antigen-binding sites found in the variable regions of both the heavy and light chain regions.

[0045] In the present invention, the term "antibody" can refer not only to the complete form having two full-length light chains and two full-length heavy chains, but also to fragments of antibody molecules. A fragment of an antibody molecule means a fragment that retains at least a peptide tag (epitope) binding function, and includes scFv, Fab, F(ab'), F(ab')2, single domain, etc.

[0046] Among antibody fragments, FaB has one antigen-binding site with a structure having a light chain variable region, a heavy chain constant region, and a heavy chain first constant region (CH1). FaB' differs from FaB in that FaB' has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(F(ab')2 antibodies are produced during which the cysteine ​​residues in the hinge region of FaB' form disulfide bonds. Fv is the smallest antibody fragment having only a heavy chain variable region and a light chain variable region, and a double chain Fv (dsFv) has a heavy chain variable region linked to a light chain variable region by a disulfide bond, while a single chain Fv (scFv) has a heavy chain variable region linked to a light chain variable region by a covalent bond generally via a peptide linker. Such antibody fragments can be obtained using proteolytic enzymes or preferably constructed by genetic recombination techniques.

[0047] The monoclonal antibody of the present invention that specifically binds to CD22 can be prepared by using a whole or part of a peptide of the CD22 protein as an immunogen (or antigen). More specifically, a non-human mammal is immunized by one or more subcutaneous, intramuscular, intravenous, intrafootpad, or intraperitoneal injections of CD22, a fusion protein containing the CD22 protein, or a carrier containing the CD22 protein as an immunogen, together with an adjuvant (e.g., Freund adjuvant) that is an immunopotentiator, as necessary. The non-human mammal is a mouse, rat, hamster, guinea pig, chicken, rabbit, cat, dog, pig, goat, sheep, donkey, horse, or cow (including transgenic animals engineered to produce antibodies derived from other animals, such as transgenic mice that produce human antibodies), and more preferably a mouse, rat, hamster, guinea pig, chicken, or rabbit. Immunization is performed 1 to 4 times at intervals of about 1 to 21 days from the first immunization, and antibody-producing cells can be obtained from the immunized mammal about 1 to 10 days after the final immunization. The recovery and time interval for immunization can be appropriately changed depending on the characteristics of the immunogen used, etc.

[0048] Hybridomas secreting monoclonal antibodies can be produced according to the method of Keila and Milstein et al. (Nature, 1975, Vol. 256, p. 495-497) or methods equivalent thereto. Hybridomas can be produced by fusing antibody-producing cells contained in any one selected from the group consisting of spleen, lymph node, bone marrow or tonsil, preferably spleen, collected from an animal other than human immunized as described above with myeloma cells derived from a mammal that does not produce autoantibodies. The mammal may be a mouse, rat, guinea pig, hamster, chicken, rabbit or human, preferably a mouse, rat, chicken or human.

[0049] For cell fusion, for example, a method using a fusion promoter containing polyethylene glycol or Sendai virus or an electric pulse is used, and for example, antibody-producing cells and infinitely proliferative mammalian cells are suspended in a fusion medium containing a fusion promoter at a ratio of about 1:1 to 1:10, and incubated in this state for about 1 to 5 minutes at about 30 to 40° C. As the fusion medium, for example, a typical common medium including MEM medium, RPMI1640 medium, and Iscove's Modified Dulbecco's Medium may be used, and it is preferable to remove serum such as bovine serum.

[0050] The method of screening for hybridoma clones producing the monoclonal antibodies includes first transferring the fused cells obtained as described above to a selection medium such as HAT medium and culturing them at about 30 to 40°C for about 3 days to 3 weeks to kill cells other than the hybridomas. Next, the hybridomas are cultured in a microtiter plate or the like, and then a portion showing increased reactivity between the culture supernatant and the immunogen used in the immune reaction of the animal other than human described above is found using an immunoassay method such as RIA (radioactive substance-marked immuno antibody) or ELISA (enzyme-linked immunosorbent assay). The clones producing the monoclonal antibodies found above exhibit specific binding ability to the immunogen.

[0051] The monoclonal antibody of the present invention can be obtained by culturing such hybridomas in vivo or in vivo. For the culture, a conventional method for culturing cells derived from a mammal is used, and for collecting the monoclonal antibody from the culture, a conventional method for purifying antibodies in general is used. Examples of the respective methods include salting out, dialysis, filtration, concentration, centrifugation, fractional precipitation, gel filtration chromatography, ion exchange chromatography, affinity chromatography, high performance liquid chromatography, gel electrophoresis, isoelectric focusing, etc., which are applied in combination as necessary. The purified monoclonal antibody is then concentrated and dried to form a liquid phase or solid phase depending on the application.

[0052] Furthermore, the monoclonal antibodies of the present invention can be obtained by synthesizing genes in which DNA encoding the heavy and light chain variable regions are linked to known DNA encoding the normal regions of the heavy and light chains (see, for example, JP 2007-252372 A) by PCR or chemical synthesis, transplanting the genes into a known expression vector that enables expression of the genes (such as pCDNA 3.1 (sold by Invitrogen)) to produce a transformant, expressing the vector in a host such as CHO cells or E. coli to produce an antibody, and purifying the antibody from the culture medium using a protein A or G column or the like.

[0053] In a specific exemplary embodiment of the present invention, in order to generate an antibody that specifically binds to CD22, hybridomas producing anti-CD22 antibodies were generated and screened, and an antibody (scFv) that specifically binds to CD22 was selected and named 2G1.

[0054] The 2G1 antibody was confirmed to consist of a light chain variable region including a CDR1 region (GFSLTSYDI) represented by the amino acids of SEQ ID NO: 1, a CDR2 region (IWTGGGT) represented by the amino acids of SEQ ID NO: 2, and a CDR3 region (VPHYYGYAMDYW) represented by the amino acids of SEQ ID NO: 3, and a light chain variable site including a CDR1 region (QDINKY) represented by the amino acids of SEQ ID NO: 4, and a CDR3 region (LQYDNLLT) represented by the amino acids of SEQ ID NO: 5 and SEQ ID NO: 6.

[0055] Specifically, it was confirmed that the 2G1 antibody comprises a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 7 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 8, the heavy chain variable region being encoded by the base sequence of SEQ ID NO: 9, and the light chain variable region being encoded by the base sequence of SEQ ID NO: 10.

[0056] In another specific embodiment of the present invention, humanized antibodies were prepared by modifying the anti-CD22 antibody 2G1 to have a structure corresponding to that of a human, and were designated 2G1(V4) and 2G1(V12).

[0057] The heavy chain variable region CDR and the light chain variable region CDR of 2G1(V4) and 2G1(V12) are the same as those of 2G1, and the remaining portions except for the CDR portions are humanized. Preferably, 2G1(V4) is composed of a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 11 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 12, and the heavy chain variable region of the 2G1(V12) antibody can be encoded by the nucleotide sequence of SEQ ID NO: 13, and the light chain variable region can be encoded by the nucleotide sequence of SEQ ID NO: 14.

[0058] Alternatively, 2G1(V12) can be composed of a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 15 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 16, and the heavy chain variable region of the 2G1(V12) antibody can be encoded by the nucleotide sequence of SEQ ID NO: 17, and the light chain variable region can be encoded by the nucleotide sequence of SEQ ID NO: 18.

[0059] The CD22-specific antibody of the present invention is a single-chain variable fragment (scFv) and can be constructed by genetic recombination techniques so that the heavy chain variable region and the light chain variable region can be linked via a linker. The linker is preferably represented by the amino acid sequence of SEQ ID NO: 19 or can be encoded by the nucleotide sequence of SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22, but is not limited thereto.

[0060] When linked as light chain variable region-linker-light chain variable region, the 2G1 antibody (mouse antibody) may be represented by the amino acid sequence of SEQ ID NO: 23 or may be encoded as the nucleotide sequence of SEQ ID NO: 24, the 2G1(V4) antibody may be represented by the amino acid sequence of SEQ ID NO: 25 or may be encoded as the nucleotide sequence of SEQ ID NO: 26, and the 2G1(V12) antibody may be represented by the amino acid sequence of SEQ ID NO: 27 or may be encoded by the nucleotide sequence of SEQ ID NO: 28.

[0061] In another aspect, the invention relates to a polynucleotide encoding an antibody that specifically binds to CD22.

[0062] In the present invention, the term "polynucleotide" generally refers to an isolated nucleic acid molecule of any length, deoxyribonucleotides or ribonucleotides, or analogs thereof. In some embodiments, a polynucleotide of the present invention is (1) in vitro amplification, such as polymerase chain reaction (PCR) amplification; (2) Cloning and recombination; (3) purification, such as cleavage and gel electrophoretic separation; (4) synthesis, such as chemical synthesis; preferably, the isolated polynucleotide is produced by recombinant DNA technology. In the present invention, nucleic acids for encoding antibodies or antigen-binding fragments thereof can be produced by a variety of methods known in the art, including, but not limited to, restriction fragment operation of synthetic oligonucleotides or application of SOE PCR.

[0063] In yet another aspect, the present invention relates to a vector comprising a polynucleotide encoding an antibody that specifically binds to CD22, and a recombinant cell transformed with said vector.

[0064] In the present invention, the term "expression vector" refers to a gene preparation that contains the necessary regulatory elements, such as a promoter, so that the gene of interest can be expressed in a suitable host cell. The vector can be selected from one or more of the following: a plasmid, a retroviral vector, and a lentiviral vector. When transformed into a suitable host, the vector can replicate and function independently of the host genome, or in some cases, can be integrated into the genome itself.

[0065] Furthermore, the vector may contain expression control elements that allow the coding region to be expressed correctly in a suitable host. Such control elements are well known to those skilled in the art and may include, for example, promoters, ribosome binding sites, enhancers, and other control elements for regulating gene transcription or mRNA translation. The specific structure of the expression control sequence may vary depending on the function of the species or cell type, but usually includes 5' non-transcribed sequences, such as TATA box, cap sequence, CAAT sequence, etc., involved in transcription initiation and translation initiation, respectively, and 5' or 3' non-translated sequences. For example, the 5' non-transcribed expression control sequence may include a promoter region that may include a promoter sequence for transcription and control of the functionally linked nucleic acid.

[0066] In the present invention, the term "promoter" refers to a minimal sequence sufficient to direct transcription. In addition, promoter structures sufficient to express regulatable promoter-dependent genes that are cell type specific or induced by external signals or sanctions can be included, and such structures can be located at the 5' or 3' portion of the gene. Both conserved and inducible promoters are included. Promoter sequences can be derived from prokaryotes, eukaryotes, or viruses.

[0067] In the present invention, the term "transformant" refers to a cell transformed by introducing a vector having a polynucleotide encoding one or more target proteins into a host cell, and methods for producing a transformant by introducing an expression vector into a host cell include the calcium phosphate method or the calcium chloride / rubidium chloride method described in the literature (Sambrook, J., et al., Molecular Cloning, A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory, 1.74, 1989), electroporation, electroinjection, chemical treatment methods such as PEG, and methods using a gene gun.

[0068] When the transformant expressing the vector is cultured in a nutrient medium, the antibody protein can be produced and isolated in large quantities. The medium and culture conditions can be appropriately selected from those commonly used depending on the host cell. Conditions such as temperature, medium pH, and culture time must be appropriately adjusted so as to be suitable for cell growth during culture and mass production of protein.

[0069] The vector according to the invention can be transformed into a host cell, preferably a mammalian cell, for the production of the antibody. A number of suitable host cell lines capable of expressing intact glycosylated proteins have been developed in the art and include COS-1 (e.g., ATCC CRL 1650), COS-7 (e.g., ATCC CRL-1651), HEK293, BHK21 (e.g., ATCC CRL-10), CHO (e.g., ATCC CRL 1610) and BSC-1 (e.g., ATCC CRL-26) cell lines, Cos-7 cells, CHO cells, hep G2 cells, P3X63Ag8653, SP2 / 0-Agl4, 293 cells, HeLa cells, etc., which are readily available, for example, from ATCC (American Type Culture Collection, USA). Preferred host cells include cells of lymphoid origin, such as melanoma and lymphoma cells.

[0070] Chimeric antigen receptor targeting CD22 From another viewpoint, the present invention provides CD22 binding domain;transmembrane domain; a chimeric antigen receptor (CAR) comprising a costimulatory domain; and an intracellular signaling domain, The present invention relates to a chimeric antigen receptor that targets CD22, characterized in that the CD22-binding domain is a humanized antibody or a fragment thereof that specifically binds to CD22, comprising a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 11 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 12; or a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 15 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 16.

[0071] In the present invention, the term "chimeric antigen receptor (CAR)" generally refers to a fusion protein that contains an extracellular domain capable of binding to an antigen and one or more intracellular domains. CAR is an important part of chimeric antigen receptor T cells (CAR-T) and can contain an antigen-binding domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain. CAR can be combined with a T cell receptor-activating intracellular domain based on the antigen (e.g., CD22) specificity of the antibody. Genetically modified CAR-expressing T cells can specifically identify and eliminate target antigen-expressing malignant cells.

[0072] In the present invention, the term "CD22 binding domain" generally refers to a domain that can specifically bind to CD22 protein. For example, the CD22 binding domain can include an anti-CD22 antibody or a fragment thereof that can specifically bind to the human CD22 polypeptide or a fragment thereof expressed in B cells.

[0073] In the present invention, the terms "binding domain", "extracellular domain", "extracellular binding domain", "antigen-specific binding domain" and "extracellular antigen-specific binding domain" can be used interchangeably and refer to a CAR domain or fragment having the ability to specifically bind to a target antigen (e.g., CD22).

[0074] In the present invention, the anti-CD22 antibody or a fragment thereof is the above-mentioned anti-CD22 antibody, and is a monoclonal antibody (monoclonal antibody), preferably a scFv (single chain variable fragment). Specifically, the anti-CD22 antibody or a fragment thereof can be prepared using the 2G1(V4) or 2G1(V12) antibody, which is a humanized antibody specific to CD22 of the present invention.

[0075] In the present invention, the chimeric antigen receptor may be a bispecific chimeric antigen receptor further comprising a B cell surface marker binding domain in addition to the CD22 binding domain, and the B cell surface marker may be CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD53, CD72, CD74, CD75, CD77, CD79a, CD79B, CD80, CD81, CD82, CD83, CD84, CD85 or CD86, preferably CD19.

[0076] In the present invention, a signal peptide may be further contained at the N-terminus of the CD22-binding domain, and the "signal peptide" generally refers to a peptide chain for inducing protein delivery.

[0077] The signal peptide may be a short peptide having a length of 5 to 30 amino acids, and in the present invention, the amino acid sequence of SEQ ID NO:36 is preferably used.

[0078] In the present invention, the antibody may further include a hinge region located between the C-terminus of the CD22-binding domain and the N-terminus of the transmembrane domain, and the hinge region is derived from CD8α and may preferably be represented by the amino acid sequence of SEQ ID NO:37.

[0079] The "hinge region" generally refers to the joining region between the antigen-binding region and the immune cell Fc receptor (FcR) binding region.

[0080] In the present invention, the term "transmembrane domain" generally refers to a domain of a CAR that passes through a cell membrane and plays a role in signal transduction by being linked to an intracellular signaling domain. The transmembrane domain may be derived from a protein selected from the group consisting of CD8α, CD4, CD28, CD137, CD80, CD86, CD152 and PD1, and may preferably be represented by the amino acid sequence of SEQ ID NO:38.

[0081] In the present invention, "costimulatory domain" generally refers to intracellular domain that can provide immune stimulatory molecule, which is a cell surface molecule required for effective response of lymphocyte to antigen.The above-mentioned costimulatory domain includes the costimulatory domain of CD28, and can include the costimulatory domain of TNF receptor family, such as the costimulatory domain of OX40 and 4-1BB, and can preferably be 4-1BB, which is represented by the amino acid sequence of SEQ ID NO:39.

[0082] In the present invention, the term "intracellular signaling domain" generally refers to a domain that is located intracellularly and can transmit a signal. In the present invention, the intracellular signaling domain is the intracellular signaling domain of a chimeric antigen receptor. For example, the intracellular signaling domain can be selected from the CD3ζ intracellular domain, the CD28 intracellular domain, the CD28 intracellular domain, the 4-1BB intracellular domain, and the OX40 intracellular domain, and can preferably be the CD3ζ represented by the amino acid sequence of SEQ ID NO:40.

[0083] Polynucleotides encoding chimeric antigen receptors and chimeric antigen receptor expression vectors In yet another aspect, the present invention relates to a polynucleotide encoding a chimeric antigen receptor (CAR).

[0084] In the present invention, a polynucleotide encoding a chimeric antigen receptor (CAR) may include a polynucleotide encoding a CD22 binding domain; a polynucleotide encoding a transmembrane domain; a polynucleotide encoding a costimulatory domain; and a polynucleotide encoding an intracellular signaling domain.

[0085] The polynucleotide encoding the CD22 binding domain may be a polynucleotide encoding a humanized 2G1(V4) or 2G1(V12) antibody specific to CD22 of the present invention, in the form of an scFv in which the light chain variable region and the heavy chain variable region are linked by a linker, and the specific base sequence is as described above.

[0086] Preferably, the polynucleotide encoding the chimeric antigen receptor (CAR) of the present invention is a 2G1 (V4) antibody represented by the base sequence of SEQ ID NO: 26 or a 2G1 (V12) antibody represented by the base sequence of SEQ ID NO: 28; A transmembrane domain represented by the nucleotide sequence of SEQ ID NO: 32; 4-1BB (costimulatory domain) represented by the base sequence of SEQ ID NO: 33; and It may include CD3ζ (intracellular signaling domain); represented by the base sequence of SEQ ID NO: 34.

[0087] When a signal peptide is contained at the N-terminus of the CD22-binding domain, the signal peptide represented by the nucleotide sequence of SEQ ID NO: 30 may be further contained. Alternatively, a polynucleotide encoding a hinge region may be further contained between the polynucleotide encoding the CD22-binding domain and the transmembrane domain, and preferably the CD8 hinge region represented by the nucleotide sequence of SEQ ID NO: 31.

[0088] In yet another aspect, the present invention relates to a vector comprising a polynucleotide encoding a chimeric antigen receptor (CAR).

[0089] In the present invention, the vector is a recombinant viral vector, preferably a lentiviral vector, which comprises an operably linked EF1α promoter; a polynucleotide encoding a signal peptide; a polynucleotide encoding a CD22-binding domain; a polynucleotide encoding a transmembrane domain; and a polynucleotide encoding an intracellular signaling domain; and may further comprise a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) to increase protein expression (FIG. 3).

[0090] The EF1α promoter is represented by the base sequence of SEQ ID NO:29, and may, if necessary, contain a sequence that is 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence of SEQ ID NO:27.

[0091] Additionally, the promoter is operably linked to drive expression of the CD22 binding domain, an anti-CD22 antibody (scFv).

[0092] In a specific exemplary embodiment of the present invention, a lentiviral vector into which a polynucleotide encoding CD22-CAR was inserted was prepared, and 293FT cells were transfected with the prepared vector to prepare CD22-CAR-expressing cells, as shown in Figure 3. Furthermore, as shown in Figure 5, it was confirmed that a chimeric antigen receptor targeting CD22 was expressed in the prepared CD22-CAR-expressing cells.

[0093] Biological methods for introducing polynucleotide into host cells include the use of DNA and RNA vectors.Viral vectors, especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, for example human cells.Other viral vectors can be derived from lentivirus, poxvirus, herpes simplex virus, adenovirus and adeno-associated virus, etc.

[0094] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., artificial membrane vesicle). Other methods are available for state-of-the-art targeted delivery of nucleic acids, such as delivery of polynucleotides using targeted nanoparticles or other suitable submicrometer delivery systems.

[0095] When a non-viral delivery system is used, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of nucleic acid into host cells (in vitro or in vivo). In another embodiment, the nucleic acid can be associated with lipid. The nucleic acid associated with lipid can be encapsulated in the aqueous interior of the liposome, interspersed in the lipid bilayer of the liposome, bound to the liposome via a linking molecule associated with both the liposome and the oligonucleotide, entrapped within the liposome, complexed with the liposome, dispersed in a lipid-containing solution, mixed with lipid, combined with lipid, contained as a suspension in lipid, contained or complexed with micelles, or associated differently from lipid. The lipid, lipid / DNA or lipid / expression vector association composition is not limited to any particular structure in solution.

[0096] Chimeric antigen receptor (CAR)-expressing immune effector cells In yet another aspect, the present invention relates to an immune effector cell that contains a polynucleotide encoding a humanized antibody-based chimeric antigen receptor (CAR) specific for CD22 or a vector comprising a polynucleotide encoding a chimeric antigen receptor (CAR), and expresses the humanized antibody-based chimeric antigen receptor (CAR) specific for CD22.

[0097] In the present invention, the immune effector cell may be an isolated cell derived from a mammal, preferably a T cell, a B cell, a natural killer (NK) cell, a dendritic cell, a bone marrow cell, a monocyte, or a macrophage, more preferably a T cell.

[0098] In the present invention, immune effector cells expressing a chimeric antigen receptor (CAR) can be produced by introducing a CAR vector of the present invention into immune effector cells, such as T cells or NK cells.

[0099] Specifically, the CAR vector can be introduced into cells by methods known in the art, such as electroporation, lipofectamine 2000 (Invitrogen), etc. For example, immune effector cells can be transfected with lentiviral vectors to ensure long-term and stable expression of target genes by integrating the viral genome carrying the CAR molecule into the host genome. In another example, a transposable element can be used to introduce the CAR transport plasmid and the transferase transport plasmid into target cells. In another example, the CAR molecule can be added to the genome by gene editing methods (e.g., CRISPR / Cas9).

[0100] Immune effector cells for preparing immune effector cells expressing chimeric antigen receptors (CARs) can be obtained from a subject, where "subject" includes a living organism (e.g., a mammal) capable of eliciting an immune response. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infected site, ascites, pleural effusion, splenic tissue, and tumors.

[0101] T cells can be obtained from a unit of blood collected from a subject using a number of techniques known to those of skill in the art, such as Ficoll™ isolation. Cells from the blood are obtained by isolated export, and the isolated export product typically includes T cells, lymphocytes, including monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets.

[0102] Cells collected by separation export can be washed to remove the plasma fraction and place the cells in an appropriate buffer or medium for subsequent processing steps. T cells lyse red blood cells and dissolve them in, for example, PERCOLL. TM Monocytes are isolated from peripheral blood lymphocytes by depletion of monocytes by gradient centrifugation or by countercurrent centrifugation.

[0103] In yet another specific exemplary embodiment of the present invention, CD22-CAR-T cells were prepared by isolating activated T cells from peripheral blood mononuclear cells (PBMCs) and then transducing the CD22-CAR lentivirus into the T cells, as shown in Figures 6 and 7. Specifically, humanized 2G1(V4) and 2G1(V12) were used to prepare CD22-CAR-T cells, respectively.

[0104] To confirm the activity of the generated CD22-CAR-T cells, we confirmed the CD22 peptide-binding ability of CD3, CD4, or CD8-activated CD22-CAR-T cells.

[0105] As shown in Figure 8, it was confirmed that the CD22-CAR-T cells prepared in the present invention bound to the CD22 peptide.

[0106] In yet another specific exemplary embodiment of the present invention, the apoptotic effect of CD22-CAR-T cells on target cells was confirmed, and as a result, as shown in Figure 9, it was confirmed that CD22-CAR-T cells specifically exhibited an apoptotic effect on U2932 cells and NALM6 cells expressing CD22.

[0107] In other words, the chimeric antigen receptors based on the humanized anti-CD22 antibodies (2G1(V4) and 2G1(V12)) of the present invention and CAR-T cells using the same can be usefully used as compositions for preventing or treating diseases associated with B cells or CD22 expression.

[0108] Bispecific chimeric antigen receptors (CARs) targeting CD19 and CD22 In yet another aspect, the present invention provides a method for producing a composition comprising: CD19-binding domain and CD22-binding domain; transmembrane domain; a costimulatory domain; and 1. A bispecific chimeric antigen receptor comprising an intracellular signaling domain, Here, the present invention relates to a bispecific chimeric antigen receptor (CD19×CD22 bispecific CAR) targeting CD19 and CD22, characterized in that the CD22-binding domain is an antibody or a fragment thereof that specifically binds to CD22, comprising a heavy chain variable region including a CDR1 region represented by the amino acids of SEQ ID NO: 1, a CDR2 region represented by the amino acids of SEQ ID NO: 2, and a CDR3 region represented by the amino acids of SEQ ID NO: 3; and a CDR1 region represented by the amino acids of SEQ ID NO: 4, a CDR2 region represented by the amino acids of SEQ ID NO: 5, and a CDR3 region represented by the amino acids of SEQ ID NO: 6.

[0109] In the present invention, the antibody or fragment thereof that specifically binds to CD22 may be an anti-CD22 antibody consisting of a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 7 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 8, or a humanized anti-CD22 antibody consisting of a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 11 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 12; or a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 15 and a light chain variable region represented by the amino acid sequence of SEQ ID NO: 16.

[0110] In the present invention, a bispecific or bivalent chimeric antigen receptor is a CAR that can simultaneously bind to two different types of antigens. In the present invention, preferably, a bispecific chimeric antigen receptor that targets both CD19 and CD22 is prepared, and the CD19 binding domain can be any known anti-CD19 antibody sequence without limitation.

[0111] The specific details of the chimeric antigen receptor are the same as those described above, and the CD19-binding domain and the CD22-binding domain of the bispecific chimeric antigen receptor are linked in the form of a loop (LoopCAR) as shown in Figure 11. That is, they can be linked in the order of the light chain variable region of an antibody that specifically binds to CD19 (CD19VL)-the heavy chain variable region of an antibody that specifically binds to CD22 (CD22VH)-the light chain variable region of an antibody that specifically binds to CD22 (CD22VL)-the heavy chain variable region of an antibody that specifically binds to CD19 (CD19VH).

[0112] The light chain variable site of the antibody that specifically binds to CD19 may include a CDR1 region represented by the amino acid sequence of SEQ ID NO: 44, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 45, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 46, and may preferably be represented by the amino acid sequence of SEQ ID NO: 48.

[0113] The heavy chain variable region of the antibody that specifically binds to CD19 may include a CDR1 region represented by the amino acid sequence of SEQ ID NO: 41, a CDR2 region represented by the amino acid sequence of SEQ ID NO: 42, and a CDR3 region represented by the amino acid sequence of SEQ ID NO: 43, and may preferably be represented by the amino acid sequence of SEQ ID NO: 47.

[0114] The CD19-binding domain and the CD22-binding domain can be prepared by gene recombination technology so that they can be linked by a linker, and preferably, CD19VL and CD22VH or CD22VL and CD19VH can be linked by a linker represented by the amino acid sequence of SEQ ID NO: 51 (linker in FIG. 11), and CD22VH and CD22VL can be linked by a linker represented by the amino acid sequence of SEQ ID NO: 54 (linker 1 in FIG. 11), but are not limited thereto, and any amino acid sequence that does not affect the antibody activity can be used.

[0115] Polynucleotides encoding CD19 / CD22-targeting bispecific chimeric antigen receptors and CD19 / CD22-targeting bispecific chimeric antigen receptor expression vectors In yet another aspect, the present invention relates to a polynucleotide encoding a bispecific chimeric antigen receptor that targets CD19 and CD22.

[0116] In the present invention, a polynucleotide encoding a bispecific chimeric antigen receptor may comprise a polynucleotide encoding a CD19-binding domain and a polynucleotide encoding a CD22-binding domain; a polynucleotide encoding a transmembrane domain; a polynucleotide encoding a costimulatory domain; and a polynucleotide encoding an intracellular signaling domain.

[0117] Preferably, the polynucleotide encoding the bispecific chimeric antigen receptor of the present invention comprises a light chain variable region of an antibody that specifically binds to CD19 (CD19VL; SEQ ID NO:50)-a heavy chain variable region of an antibody that specifically binds to CD22 (CD22VH; SEQ ID NO:9, SEQ ID NO:13, or SEQ ID NO:17)-a light chain variable region of an antibody that specifically binds to CD22 (CD22VL; SEQ ID NO:10, SEQ ID NO:14, or SEQ ID NO:18)-a heavy chain variable region of an antibody that specifically binds to CD19 (CD19VH; SEQ ID NO:49); A transmembrane domain represented by the nucleotide sequence of SEQ ID NO: 32; 4-1BB (costimulatory domain) represented by the base sequence of SEQ ID NO: 33; and It may include CD3ζ (intracellular signaling domain); represented by the base sequence of SEQ ID NO: 34.

[0118] When the "CD19VL and CD22VH" or "CD22VL and CD19VH" are linked by a linker represented by the amino acid sequence of SEQ ID NO: 51, the polynucleotide of the linker may be represented by the base sequence of SEQ ID NO: 52 or SEQ ID NO: 53, and when the "CD22VH and CD22VL" are linked by a linker represented by the amino acid sequence of SEQ ID NO: 54, the polynucleotide for the linker may be represented by the base sequence of SEQ ID NO: 55, but is not limited thereto, and a polynucleotide encoding any amino acid sequence that does not affect antibody activity may be used.

[0119] When a signal peptide is contained at the N-terminus of the CD19 / CD22-binding domain, the signal peptide represented by the nucleotide sequence of SEQ ID NO: 30 may be further contained. In addition, a polynucleotide encoding a hinge region may be further contained between the polynucleotide encoding the CD22-binding domain and the transmembrane domain, and preferably the CD8 hinge region represented by the nucleotide sequence of SEQ ID NO: 31.

[0120] In yet another aspect, the present invention relates to a vector comprising a polynucleotide encoding a bispecific chimeric antigen receptor.

[0121] In a specific embodiment of the invention, the vector is a recombinant viral vector, preferably a lentiviral vector, comprising an operably linked EF1α promoter; a polynucleotide encoding a signal peptide; a polynucleotide encoding a CD19-binding domain and a CD22-binding domain; a polynucleotide encoding a transmembrane domain; a polynucleotide encoding an intracellular signaling domain; and may further comprise a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) for increased protein expression ( FIG. 12 ).

[0122] The EF1α promoter is represented by the base sequence of SEQ ID NO:29, and may, if necessary, contain a sequence that is 90% or more, 93% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence of SEQ ID NO:27.

[0123] Furthermore, the promoter is functionally linked to induce expression of the CD19×CD22 binding domain of the anti-CD19 / CD22 antibody (CD19VL-CD22VH-CD22VL-CD19VH), and the specific contents of the vector are as described above.

[0124] In a specific exemplary embodiment of the present invention, a lentiviral vector was prepared by inserting a polynucleotide encoding CD19×CD22-CAR, and 293FT cells were transfected with the prepared vector to prepare CD19×CD22-CAR-expressing cells, as shown in Figure 12. Furthermore, as shown in Figures 13 and 14, it was confirmed that a bispecific antigen receptor targeting CD19 and CD22 was expressed in the prepared CD19×CD22-CAR-expressing cells.

[0125] Immune effector cells expressing bispecific chimeric antigen receptors targeting CD19×CD22 In yet another aspect, the present invention relates to an immune effector cell comprising a polynucleotide encoding a bispecific chimeric antigen receptor (CAR) or a vector comprising a polynucleotide encoding a bispecific chimeric antigen receptor (CAR) and expressing said bispecific chimeric antigen receptor (CAR).

[0126] In the present invention, the immune effector cell can be an isolated cell derived from a mammal, preferably a T cell, a B cell, a natural killer (NK) cell, a dendritic cell, a bone marrow cell, a monocyte or a macrophage, more preferably a T cell. Alternatively, the specific details regarding the chimeric antigen receptor-expressing immune effector cell are as described above.

[0127] In a specific embodiment of the present invention, activated T cells were isolated from peripheral blood mononuclear cells (PBMCs) in a similar manner to CD22-CAR-T cell preparation ( FIG. 7 ), and then CD19×CD22-CAR lentivirus was transduced into T cells to generate CD19×CD22-CAR-T cells, specifically, CD19×CD22-CAR-T cells were generated using 2G1 antibody (mouse), humanized 2G1 (V4), and 2G1 (V12), respectively.

[0128] To confirm the activity of the generated CD19×CD22-CAR-T cells, we confirmed the binding ability of CD3, CD4, or CD8-activated CD19×CD22-CAR-T cells to CD22 and CD19 peptides.

[0129] As shown in Figure 16, the CD19×CD22-CAR-T cells prepared according to the present invention were confirmed to bind to both CD22 peptide and CD19 peptide.

[0130] In another specific exemplary embodiment of the present invention, in order to confirm the activation of CD19×CD22-CAR-T cells, the expression level of IFNγ by CD19×CD22-CAR-T cells was confirmed in the presence of target cells. As a result, as shown in Figures 17A to 17C, it was confirmed that T cells were not activated in K562 cells that do not express CD19 and CD22, whereas T cells were activated in the presence of NALM6 cells that express CD19 and CD22, and IFNγ expression was increased.

[0131] In another specific exemplary embodiment of the present invention, the apoptotic effect of CD19×CD22-CAR-T cells on target cells was confirmed, and as shown in FIG. 18, it was confirmed that CD19×CD22-CAR-T cells exhibited an apoptotic effect specifically on NALM6 cells expressing CD19 and CD22.

[0132] Furthermore, in yet another specific exemplary embodiment of the present invention, in order to confirm the antitumor effect of CD19×CD22-CAR-T cells, and in another specific embodiment of the present invention, in order to confirm the antitumor effect of CD19×CD22-CAR-T cells, CD19×CD22-CAR-T cells produced using humanized 2G1-V4 antibody were intratumorally injected into a mouse model xenografted with tumor cells, and changes in tumor size were observed. As a result, as shown in FIG. 19, it was confirmed that the antitumor effect of the CD19×CD22-CAR-T cells of the present invention was superior to that of the palivizumab-CAR-T cells based on an antibody binding to the SV40 virus used as a positive control group, and the CD19×CD22-CAR-T cells were administered at a dose of 5×10 6 It was confirmed that when treated with 50 or more cells, most of the tumor cells were killed and no tumor tissue was observed.

[0133] That is, the bispecific chimeric antigen receptor targeting CD19×CD22 and CD19×CD22-CAR-T cells of the present invention can be usefully used as compositions for preventing or treating diseases associated with B cells or CD19×CD22 expression.

[0134] Compositions for preventing or treating B cell-mediated diseases or diseases mediated by CD19xCD22 expression From another aspect, the present invention relates to a pharmaceutical composition for preventing or treating a disease mediated by B cells, comprising a humanized antibody that specifically binds to CD22, an immune effector cell that expresses a chimeric antigen receptor that targets CD22, or an immune effector cell that expresses a bispecific chimeric antigen receptor that specifically binds to CD19×CD22.

[0135] In the present invention, the B cell may preferably be a cell expressing CD19 or CD22, and the disease may be selected from the group consisting of tumor / cancer, lymphoma, non-Hogkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), Burkitt's lymphoma and mantle cell lymphoma.

[0136] In the present invention, the composition can comprise a therapeutic agent for a B cell mediated disease, which can be present covalently linked to an antibody that specifically binds to CD19 or CD22, or can be administered in combination with the CD22-CAR immune effector cells or CD19xCD22-CAR immune effector cells of the present invention.

[0137] Therapeutic agents include small molecule drugs, peptide drugs, toxins (eg, cytotoxins), and the like.

[0138] The small molecule drugs may be compounds that exhibit a desired pharmacological activity and generally have a molecular weight of about 800 Da or less or 2000 Da or less. Small inorganic molecules refer to molecules that do not contain any carbon atoms, whereas small organic molecules refer to compounds that contain at least one carbon atom.

[0139] The peptide drug refers to an amino acid containing polymeric compound, which includes natural and non-natural peptides, oligopeptides, cyclic peptides, polypeptides and proteins, and peptidomimetics. Peptide drugs may be obtained by chemical synthesis or may be produced from genetically encoded sources (e.g., recombinant sources). The molecular weight of peptide drugs may range from 200 Da to 10 kDa or more.

[0140] The toxin is preferably a cytotoxin, including, but not limited to, ricin, abrin, diphtheria toxin, Pseudomonas exotoxin (e.g., PE35, PE37, PE38, PE40, etc.), saporin, gelronin, American vacant antiviral protein (PAP), botulinum toxin, bryodin, momordin, and buganin.

[0141] Furthermore, the therapeutic agent can be an anti-cancer agent. Anti-cancer agents reduce the proliferation of cancer cells and include non-peptide (i.e., non-proteinaceous) compounds that combine cytotoxic and cytostatic agents. Non-limiting examples of anti-cancer agents include alkylating agents, nitroso elements, antimetabolites, antitumor antibiotics, plant (vinca) alkaloids, and steroid hormones. Peptide compounds can also be used.

[0142] The antibodies, CD22-CAR immune effector cells or CD19xCD22-CAR immune effector cells specifically binding to CD22 in said pharmaceutical compositions can be the only active components in a therapeutic or diagnostic composition or can be used together with other active components including other antibody components such as, for example, anti-T cells, anti-IFNγ or anti-LPS antibodies, or non-antibody components such as xanthines.

[0143] The pharmaceutical composition preferably comprises a therapeutically effective amount of the antibody of the present invention. As used herein, the term "therapeutically effective amount" refers to the amount of therapeutic agent required to treat, ameliorate, or prevent a target disease or condition, or refers to the amount of therapeutic agent required to exhibit a detectable therapeutic or prophylactic effect. Meaning. For some antibodies, the therapeutically effective dosage can be initially determined by cell culture assays or animal models, usually rodents, rabbits, dogs, pigs, or primates. Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can be used to determine dosages and roots useful for human administration.

[0144] The exact effective amount for a human patient will depend on the severity of the disease state, the patient's general health, the patient's age, weight and sex, diet, time of administration, frequency of administration, drug composition, reaction sensitivity and tolerance / response to treatment. The amount can be determined by routine experimentation and is within the judgement of the clinician. In general, the effective dose is 0.01-50 mg / kg, preferably 0.1-20 mg / kg, more preferably about 15 mg / kg.

[0145] Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

[0146] The dosage at which the antibodies of the present invention are administered will vary depending on the nature of the condition being treated, the grade of the malignant lymphoma or leukemia, and whether the antibodies are used at a disease preventative level or to treat an existing condition.

[0147] The frequency of administration depends on the half-life of the antibody molecule and the duration of efficacy. If the antibody molecule has a short half-life (e.g., 2-10 hours), one or more doses per day should be provided. Alternatively, if the antibody molecule has a long half-life (e.g., 2-15 days), one dose per day, one dose per week, or one dose per month or two months should be provided.

[0148] In addition, the pharmaceutical composition may contain a pharma- ceutically acceptable carrier for administration of the antibody. The carrier should not itself induce the production of antibodies harmful to the individual receiving the composition and should be non-toxic. Suitable carriers may be slowly metabolized macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, amino acid polymers, amino acid copolymers, and inactive virus particles.

[0149] Pharmaceutically acceptable salts are, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates and sulfates, or acetates, propionates, etc. Salts of organic acids such as malonic acid and benzoic acid can be used.

[0150] Pharmaceutically acceptable carriers in therapeutic compositions may further contain liquids such as water, saline, glycerol and ethanol.In addition, auxiliary substances such as wetting agents, emulsifiers or pH buffering substances may be present in such compositions.Carriers can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions for the patient to take the pharmaceutical composition.

[0151] Preferred forms for administration include those suitable for parenteral administration, for example by injection or infusion (e.g., drop-injection or continuous infusion). If the product is for infusion or injection, it can take the form of a suspension, solution or emulsion in an oily or water-soluble excipient, which may contain formulatory agents such as suspending agents, preservatives, stabilizers and / or dispersing agents. Alternatively, the antibody molecule may be in anhydrous form and reconstituted with a suitable sterile liquid before use.

[0152] Once formulated, the compositions of the invention can be administered directly to a patient. The patient to be treated can be an animal. However, it is preferred that the compositions are suitable for administration to a human patient.

[0153] The pharmaceutical composition of the present invention can be administered by any route, including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intraspinal, intraventricular, transdermal (see, for example, WO 98 / 20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, vaginal or rectal. A hypospray can be used to administer the pharmaceutical composition of the present invention. Typically, the therapeutic composition can be prepared as an injectable material in a liquid solution or suspension. Alternatively, a solid form suitable for liquid or suspension in a liquid vehicle prior to injection can be prepared.

[0154] The direct delivery of the composition can generally be by injection, subcutaneous injection, intraperitoneal injection, intravenous injection, intramuscular injection, or can be delivered to the interstitial space of tissue.Furthermore, the composition can be administered at the wound site.The dose treatment can be a single dose schedule or a multiple dose schedule.

[0155] The active ingredient in the composition can be an antibody molecule. It is itself sensitive to degradation in the gastrointestinal tract. Therefore, when the composition is administered by a route that uses the gastrointestinal tract, the composition will need to contain an agent that protects the antibody from degradation but releases the antibody once absorbed from the gastrointestinal tract.

[0156] A thorough discussion of pharma- ceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Publishing Company, NJ, 1991).

[0157] In the following, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided to facilitate understanding of the present invention, and are not intended to limit the scope of the present invention.

[0158] Example 1: Generation and selection of antibodies that specifically bind to CD22 To select antibodies specific to the CD22 peptide, hybridomas producing antibodies that bind to CD22 were generated and the antibodies were selected.

[0159] First, spleen cells were isolated by immunization with CD22 protein (ACRObiosystems Inc., cat#CD2-H52H8, USA) and fused with mouse myeloma cells to produce hybridoma cells.

[0160] Mouse myeloma cells used for cell fusion cannot survive in HAT medium because they do not have the hypoxanthine guanidine phosphoribosyl-transferase (HGPRT) gene, but hybridomas can survive in HAT medium by fusing with spleen cells. Since only hybridomas can be grown in HAT medium, hybridomas are generally grown in HAT medium until they are established.

[0161] Among the grown hybridomas, hybridomas producing antibodies that bind to CD22 were selected by limiting dilution. First, the number of cells was adjusted to 1 cell or less per 96 well, and then ELISA was used to confirm whether the antibody obtained from a clone grown from a single cell binds to CD22, and clones that bind to CD22 were selected. The above process was repeated three times to select hybridomas producing antibodies that bind to CD22. In this way, antibodies that bind to CD22 were obtained.

[0162] This antibody was named 2G1, and its nucleotide sequence and amino acid sequence were analyzed. The sequence information of the heavy chain variable region and the light chain variable region of each antibody based on the sequence analysis results is shown in Table 1 below, and the underlined parts in Table 1 indicate the complementarity determining regions (CDRs).

[0163] [Table 1]

[0164] Example 2: Preparation of humanized antibodies based on the 2G1 antibody The 2G1 antibody selected in Example 1 was modified to have a structure corresponding to that of a human antibody to prepare a humanized antibody.

[0165] Specifically, the mouse 2G1 antibody was constructed into a humanized antibody by CDR grafting, in which the CDRs of a mouse antibody that binds to CD22 were replaced with those of a human antibody, using the germline sequence of the human antibody as a frame. The humanized antibodies were named 2G1(V4) and 2G1(V12), and their amino acid sequences were analyzed. The sequence information of the heavy chain variable region and the light chain variable region of the antibody based on the sequence analysis is shown in Tables 2 and 3 below, and the underlined parts in Tables 2 and 3 indicate the complementarity determining regions (CDRs).

[0166] [Table 2]

[0167] [Table 3]

[0168] Example 3: Confirmation of specificity of selected antibodies to CD22 In the present invention, flow cytometry was performed to confirm the specificity of the 2G1 antibody (mouse) of Example 1, the humanized 2G1 (V4) antibody, and the 2G1 (V12) antibody to CD22.

[0169] First, 1×10 B-cell lymphoma U2932 cells expressing CD22 were 6 The cells were reacted with 1 μg of 2G1 antibody for 30 minutes, and then the surface was stained with a secondary antibody and measured using a flow cytometer.

[0170] A PE-conjugated anti-CD22 antibody (Biolegend Inc., cat# 302506, USA) was used as a positive control, and a PE-conjugated goat anti-mouse IgG antibody (Biolegend Inc., cat# 405307, USA) was used as a secondary antibody.

[0171] As a result, as shown in FIG. 1, it was confirmed that all of the 2G1 antibody, humanized 2G1(V4) and 2G1(V12) antibodies specifically bind to CD22-expressing cells.

[0172] Example 4: Construction of CD22-targeted chimeric antigen receptor (CD22-CAR) expression vector In the present invention, a lentivirus vector expressing a chimeric antigen receptor (CAR) targeting CD22 (CD22-CAR lentivirus) was constructed using the humanized 2G1 (V4) and 2G1 (V12) antibodies prepared in Example 2.

[0173] As shown in the schematic diagram of Figure 3, EF1α promoter (SEQ ID NO:29); A polynucleotide encoding a signal peptide (SEQ ID NO:30); A polynucleotide encoding a CD22-binding domain (2G1-V4 represented by SEQ ID NO: 26 or 2G1-V12 represented by SEQ ID NO: 28); A polynucleotide encoding the CD8 hinge region (SEQ ID NO:31); a polynucleotide encoding a transmembrane domain (SEQ ID NO:32); A polynucleotide encoding 4-1BB (costimulatory domain) (SEQ ID NO:33); A polynucleotide encoding CD3ζ (intracellular signaling domain) (SEQ ID NO:34); and CAR DNA consisting of a polynucleotide encoding WPRE (SEQ ID NO: 35); was synthesized in vitro and inserted into a third generation lentiviral vector.

[0174] The lentiviral vectors were co-transfected with three vectors, pMDLg / pRRE (Addgene, cat##12251), pMD2.G (Addgene, cat##12259), and pRSV-Rev (Addgene, cat##12253), into HEK293FT cells to produce CD22-CAR lentivirus. For co-transfection, HEK293FT cells were cultured with the three vectors for 4 hours using Lipofectamine 3000 transfection kit (Invitrogen, cat#L3000-015) and Opti-MEM+GlutaMAX (gibco, cat#51985-034) medium.

[0175] We confirmed that CD22-specific CAR was expressed in HEK293FT transfected with a lentiviral vector (Figure 4B), and found that anti-CD22 antibody expression was normal, as shown in Figure 5.

[0176] Example 5: Preparation of CD22-CAR-T cells In the present invention, the CD22-CAR lentiviral vector prepared in Example 4 above was transformed into T cells to generate CD22-CAR-T cells based on humanized anti-CD22 antibodies (2G1(V4) and 2G1(V12)).

[0177] Specifically, as shown in the schematic diagram of Figure 7, peripheral blood mononuclear cells (PBMCs) were separated from blood, and then T cells were activated using T cell activation beads (Miltenyl Biotec, cat#130-091-441). The activated T cells were transduced with the CD22-CAR lentivirus produced in Example 5 above to produce CD22-CAR-T cells.

[0178] The CD22 peptide binding ability of CD22-CAR-T cells was confirmed by flow cytometry. The CD22-CAR-T cells (2G1-V4 and 2G1-V12) prepared above were classified into CD22-CAR-T cells with activated CD3, CD4, or CD8 using anti-CD3, anti-CD4, and anti-CD8 antibodies, respectively, and then reacted with FITC-CD22 peptide, and the fluorescence intensity was measured using a FACS machine.

[0179] As a result, as shown in Figure 8, it was confirmed that CD22-CAR-T cells in which CD3, CD4, or CD8 had been activated also bound to the CD22 peptide.

[0180] Example 6: Confirmation of the apoptotic effect of CD22-CAR-T cells on CD22-expressing cells In the present invention, the killing effect of target cells by CD22-CAR-T cells based on humanized anti-CD22 antibodies (2G1(V4) and 2G1(V12)) was confirmed.

[0181] K562 cells (human erythroleukemic cell line) that do not express CD22, and U2932 cells (B cell lymphoma) and NALM6 cells (human B cell precursor leukemia) that express CD22 were used as target cells, and CD22-CAR-T cells were mixed with the cells at ratios of 1:4, 1:2, 1:1, 1:0.5, and 1:0.25, respectively, and incubated for 8 hours, after which luminescence (CytoTox-Glo Cytotoxicity Assay, Promega, cat. NO G9291) was measured. The degree of apoptosis was calculated using the following formula (1) as the measured value.

[0182] [Formula 1] % Cytotoxicity = [(experimental - effector spontaneous - target spontaneous) / (target maximum - target spontaneous)] x 100 Experimental: Luminescence values ​​derived from the medium of target cells and CAR-T cell cocultures Effector Spontaneous: Luminescence values ​​derived from the culture medium of CAR-T cells only Target Spontaneous: Luminescence values ​​derived from the medium containing only target cells Target Maximum: The luminescence value derived from 100% lysis of target cells (using the Lysis Reagent)

[0183] As a result, as shown in Figures 9 and 10, it was confirmed that CD22-CAR-T cells based on humanized anti-CD22 antibodies (2G1(V4) and 2G1(V12)) specifically killed U2932 cells and NALM6 cells expressing CD22.

[0184] In the present invention, the above experiments confirmed that CD22-CAR-T cells based on humanized anti-CD22 antibodies (2G1(V4) and 2G1(V12)) specifically killed U2932 cells derived from diffuse large B-cell lymphoma and NALM6 cells derived from acute lymphoblastic leukemia.

[0185] In other words, the chimeric antigen receptors based on the humanized anti-CD22 antibodies (2G1(V4) and 2G1(V12)) of the present invention and CAR-T cells using the same can be usefully used as compositions for preventing or treating diseases associated with B cells or CD22 expression.

[0186] Example 7: Construction of a bispecific chimeric antigen receptor expression vector targeting CD19 / CD22 In the same manner as in Example 4 above, a lentiviral vector expressing a bispecific chimeric antigen receptor targeting CD19 and CD22 (CD19×CD22-CAR lentivirus) was prepared.

[0187] As shown in the schematic diagram of Figure 11, EF1α promoter (SEQ ID NO:29); A polynucleotide encoding a signal peptide (SEQ ID NO:30); a polynucleotide encoding a CD19 / CD22 binding domain; A polynucleotide encoding the CD8 hinge region (SEQ ID NO:31); a polynucleotide encoding a transmembrane domain (SEQ ID NO:32); A polynucleotide encoding 4-1BB (costimulatory domain) (SEQ ID NO:33); A polynucleotide encoding CD3ζ (intracellular signaling domain) (SEQ ID NO:34); and CAR DNA consisting of a polynucleotide encoding WPRE (SEQ ID NO: 35); was synthesized in vitro and inserted into a third generation lentiviral vector.

[0188] In the present invention, a known anti-CD19 antibody (FMC63) was used as the CD19-binding domain, and the 2G1 antibody, 2G1(V4) antibody, and 2G1(V12) antibody of the present invention were used as the CD22-binding domain.

[0189] The CD19×CD22 binding domain is linked in the order of the light chain variable region of an antibody that specifically binds to CD19 (CD19VL)-the heavy chain variable region of an antibody that specifically binds to CD22 (CD22VH)-the light chain variable region of an antibody that specifically binds to CD22 (CD22VL)-the heavy chain variable region of an antibody that specifically binds to CD19 (CD19VH) (LoopCAR), and the sequence information of the polynucleotides encoding them is as follows: CD19x2G1: CD19VL represented by the nucleotide sequence of SEQ ID NO:50-linker represented by the nucleotide sequence of SEQ ID NO:52 (linker 1 in Figure 11)-CD22VH represented by the nucleotide sequence of SEQ ID NO:9-linker represented by the nucleotide sequence of SEQ ID NO:55 (linker 6 in Figure 11)-CD22VL represented by the nucleotide sequence of SEQ ID NO:10-linker represented by the nucleotide sequence of SEQ ID NO:53 (linker 1 in Figure 11); CD19×2G1(V4): CD19VH consisting of CD19VL represented by the nucleotide sequence of SEQ ID NO:50-linker represented by the nucleotide sequence of SEQ ID NO:52 (linker 1 in FIG. 11 )-CD22VH represented by the nucleotide sequence of SEQ ID NO:13-linker represented by the nucleotide sequence of SEQ ID NO:55 (linker 6 in FIG. 11 )-CD22VL represented by the nucleotide sequence of SEQ ID NO:14-linker represented by the nucleotide sequence of SEQ ID NO:53 (linker 1 in FIG. 11 ); CD19×2G1(V12): CD19VH consisting of CD19VL represented by the base sequence of SEQ ID NO: 50-linker represented by the base sequence of SEQ ID NO: 52 (linker 1 in Figure 11)-CD22VH represented by the base sequence of SEQ ID NO: 17-linker represented by the base sequence of SEQ ID NO: 55 (linker 6 in Figure 11)-CD22VL represented by the base sequence of SEQ ID NO: 18-linker represented by the base sequence of SEQ ID NO: 53 (linker 1 in Figure 11).

[0190] The lentiviral vectors were co-transfected with three vectors, pMDLg / pRRE (Addgene, cat##12251), pMD2.G (Addgene, cat##12259), and pRSV-Rev (Addgene, cat##12253), into HEK293FT cells to produce CD19 / CD22-CAR lentivirus. For co-infection, HEK293FT cells were cultured with the three vectors for 4 hours using Lipofectamine 3000 transfection kit (Invitrogen, cat#L3000-015) and Opti-MEM + GlutaMAX (gibco, cat#51985-034) medium.

[0191] We confirmed that CD19×CD22-specific CAR was expressed in HEK293FT transfected with a lentiviral vector, and found that anti-CD19 / anti-CD22 antibody expression was normal, as shown in Figures 13 and 14.

[0192] Example 8: Preparation of CD19xCD22-CAR-T cells In the present invention, the CD19×CD22-CAR lentiviral vector prepared in Example 7 above was transformed into T cells in a manner similar to that of Example 5 to produce CD19×CD22-CAR-T cells, CD19×2G1, CD19×2G1(V4), and CD19×2G1(V12), respectively.

[0193] The ability of CD19 × CD22-CAR-T cells to bind CD22 peptide was confirmed by flow cytometry. CD19×CD22-CAR-T cells (CD19×2G1, CD19×2G1(V4), CD19×2G1(V12)) were classified into CD3-, CD4-, or CD8-activated CD19×CD22-CAR-T cells using anti-CD3, anti-CD4, or anti-CD8 antibodies, respectively, and then reacted with PE-CD19 peptide and FITC-CD22 peptide, and the fluorescence intensity was measured using a flow cytometer.

[0194] As a result, as shown in Figure 16, all CD3, CD4 or CD8 activated CD19×CD22-CAR-T cells were confirmed to bind to CD19 and CD22 peptides.

[0195] Example 9: Confirmation of activation of CD19×CD22-CAR-T cells in CD22-expressing cells In the present invention, in order to confirm that the CD19×CD22-CAR-T cells prepared in Example 8 above were activated specifically to CD22-expressing cells, the level of IFNγ expression by CD19×CD22-CAR-T cells was confirmed in the presence of target cells.

[0196] The target cells used were K562 cells (ATCC, cat#CCL-243) that do not express CD19 and CD22, and NALM6 cells (human B cell precursor leukemia) that express CD19 and CD22. CD19 / CD22-CAR-T cells were reacted with the target cells at ratios of 2:1, 1:1, 0.5:1, and 0.25:1 for a certain period of time, and then stained with surface and intra antibodies and measured using a flow cytometer (INF-r, CD4, and CD8 staining).

[0197] As a result, as shown in Figures 17A to 17C, it was confirmed that T cells were not activated in the presence of K562 cells that do not express CD19 and CD22, whereas T cells were activated in the presence of NALM6 cells that express CD19 and CD22, resulting in increased IFNγ expression.

[0198] Example 10: Confirmation of the apoptotic effect of CD19×CD22 cells on CD22 or CD19 expressing cells In the present invention, the killing effect of target cells by humanized anti-CD22 antibodies (2G1(V4)- and 2G1(V12)-based CD19×CD22-CAR-T cells) was confirmed.

[0199] K562 cells (human erythroleukemic cell line) that do not express CD19 and CD22 and NALM6 cells (human B cell precursor leukemia) that express CD19 and CD22 were used as target cells, and CD19×CD22-CAR-T cells were mixed at ratios of 1:4, 1:2, 1:1, 1:0.5, and 1:0.25, respectively, and cultured for 8 hours, after which luminescence (CytoTOX-Glo CytotOXicity Assay, Promega, cat# G9291) was measured. The degree of cell death was calculated using the measured value and formula 1 in Example 6.

[0200] As a result, as shown in Figure 18A, it was confirmed that mouse-derived 2G1-based CD19x2G1 CAR-T, 2G1 humanized antibody-based CD19x2G1(V4) CAR-T, and 2G1 another humanized antibody-based CD19x2G1(V12) CAR-T cells specifically killed NALM6 cells expressing CD22 and CD19.

[0201] In the present invention, K562 cells (ATCC, cat#CCL-243) that do not express CD19 or CD22 were used to generate three cells expressing CD19, CD22, or CD19×CD22: K562 / CD19+, K562 / CD22+, and K562 / CD19+ / CD22+, and the killing effect of target cells by CD19×2G1(V4) CAR-T cells based on humanized antibodies was confirmed. As a result, as shown in Figure 18B, it was confirmed that CD19×2G1(V4) CAR-T cells specifically kill cells expressing CD22, CD19, or CD19 / CD22.

[0202] Example 11: Confirmation of the antitumor effect of CD19 / CD22-CAR-T cells in an animal model In the present invention, the antitumor effect of CD19×CD22-CAR-T cells was confirmed using a mouse model in which tumor cells were xenografted.

[0203] 1 × 10 6 NALM6 / Luc cells were intravenously injected, and then on the 5th day, a low number (0.5 × 10 6 pieces, medium 1×10 6 pieces, many (high) 5×10 6 The positive control group received 1.25 × 10 7 Palivizumab CAR-T cells were injected into the tumor. Luminescence expressed by NAML6 / Luc cells was photographed in vitro using IVIS SpectrumCT on days 3, 8, 15, 22, and 29 after cell injection, and the antitumor effect was observed by suppressing the proliferation of NALM6 / Luc cells.

[0204] As a result, as shown in FIG. 19A, the antitumor effect of the CD19×CD22-CAR-T cells of the present invention was confirmed to be superior to that of the Palivizumab CAR-T cells derived from the scFv of the antibody Palivizumab that binds to the SV40 virus used as a positive control group and an animal group that was not injected with CAR-T. 6When treated with more than one cell, most of the tumor cells were killed, and no tumor cells expressing luminescence were observed up to 29 days after CAR-T injection.

[0205] These results are shown in the survival curve in FIG. 19B. The median survival rate was 1×10 6 , high 5×10 6 It was confirmed that all mice injected with CD19×CD22-CAR-T survived until the 29th day.

Claims

1. A CD19-binding domain and a CD22-binding domain; Transmembrane domain; A costimulatory domain; and 1. A bispecific chimeric antigen receptor comprising an intracellular signaling domain, wherein the CD22-binding domain is an antibody or an antigen-binding fragment thereof that specifically binds to CD22, the antibody or antigen-binding fragment comprising: a heavy chain variable region comprising a CDR1 region represented by the amino acids of SEQ ID NO: 1, a CDR2 region represented by the amino acids of SEQ ID NO: 2, and a CDR3 region represented by the amino acids of SEQ ID NO: 3; and a light chain variable region comprising a CDR1 region represented by the amino acids of SEQ ID NO: 4, a CDR2 region represented by the amino acids of SEQ ID NO: 5, and a CDR3 region represented by the amino acids of SEQ ID NO:

6. A bispecific chimeric antigen receptor targeting CD19 and CD22.

2. The CD19-binding domain and the CD22-binding domain are linked in the following order: light chain variable region of an antibody that specifically binds to CD19 - heavy chain variable region of an antibody that specifically binds to CD22 - light chain variable region of an antibody that specifically binds to CD22 - heavy chain variable region of an antibody that specifically binds to CD19. The bispecific chimeric antigen receptor targeting CD19 and CD22 according to claim 1.

3. The light chain variable region of the antibody that specifically binds to CD19 is represented by the amino acid sequence of SEQ ID NO: 48, and the heavy chain variable region of the antibody that specifically binds to CD19 is represented by the amino acid sequence of SEQ ID NO:

47. The bispecific chimeric antigen receptor targeting CD19 and CD22 according to claim 2.

4. the transmembrane domain being a protein selected from the group consisting of CD8α, CD4, CD28, CD137, CD80, CD86, CD152 and PD1, the costimulatory domain is a protein selected from the group consisting of CD28, 4-1BB, OX-40 and ICOS; The intracellular signaling domain is CD3ζ; The bispecific chimeric antigen receptor targeting CD19 and CD22 according to claim 1.

5. Further comprising a hinge region between the C-terminus of the binding domain and the N-terminus of the transmembrane domain; The bispecific chimeric antigen receptor targeting CD19 and CD22 according to claim 1.

6. A polynucleotide encoding a bispecific chimeric antigen receptor according to any one of claims 1 to 5.

7. A vector comprising a polynucleotide encoding the bispecific chimeric antigen receptor described in any one of claims 1 to 5.

8. A polynucleotide encoding the bispecific chimeric antigen receptor of any one of claims 1 to 5. or A vector comprising a polynucleotide encoding the bispecific chimeric antigen receptor of any one of claims 1 to 5; Includes Immune effector cells.

9. The immune effector cell of claim 8. A pharmaceutical composition for preventing or treating a B cell mediated disease.

10. The B cell mediated disease is a tumor, a lymphoma, a non-Hodgkin's lymphoma, lymphoma (NHL), aggressive NHL, recurrent aggressive NHL, recurrent delayed NHL, refractory NHL, refractory delayed NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ACLL), lymphocytic leukemia (ALL), Burkitt's lymphoma and mantle cell lymphoma, A pharmaceutical composition for preventing or treating a disease mediated by B cells according to claim 9.

Images